Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**N-phenyl pyrazoline-2** is a *synthetic small molecule* from the pyrazoline derivative family, specifically a 2-pyrazoline substituted with a phenyl group at the nitrogen. It has been experimentally investigated for its *anticancer activity*, particularly against cervical cancer (HeLa) cells. The most studied variant, often called "pyrazoline 2" or "P2," and closely related derivatives exhibit cytotoxic activity, strongly inhibiting cell proliferation, colony formation, migration, and cancer stem cell-like properties via inhibition of the epidermal growth factor receptor (EGFR) pathway. Molecular docking and in vitro studies support that N-phenyl pyrazoline-2 targets EGFR, suppressing cell viability and migration, suggesting potential as a lead compound for anticancer drug development, notably for solid tumors such as cervical, breast, and colorectal cancer[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-phenyl pyrazoline-2.